接受生物制剂治疗的老年银屑病患者:意大利经验
本研究回顾性多中心审查了266例65岁及以上正在接受生物制剂治疗的银屑病患者临床记录,基线PASI评分均值±标准差为16.5±7.1,第16周降至3.7±8,第52周降至1.2±2.1;观察期间报告25例不良事件,最常见为感染12例(48%),其次为恶性肿瘤4例(16%)。作者认为所有生物制剂在老年患者中疗效良好,不良事件发生率和类型与年轻患者相似,年龄本身不应限制治疗选择。
要点
- 266例老年银屑病患者中阿达木单抗占31.2%、乌司奴单抗占28.9%、依那西普占20.3%。
- 基线PASI均值±标准差16.5±7.1,第16周3.7±8,第52周1.2±2.1。
- 报告25例不良事件,感染12例(48%),恶性肿瘤4例(16%)。
核心结论
- 所有银屑病生物制剂在老年患者中疗效良好,不良事件发生率和类型与年轻患者相似。
- 作者认为年龄本身不应限制治疗选择。
- 需要进一步观察性研究使用多数据来源评估老年银屑病患者的长期疗效和安全性。
研究设计与样本
- 回顾性多中心临床记录审查,纳入266例65岁及以上正在接受生物制剂(依那西普、阿达木单抗、英夫利西单抗、戈利木单抗、培塞利珠单抗、乌司奴单抗或司库奇尤单抗)治疗的银屑病患者。
主要发现
- 生物制剂使用分布:阿达木单抗31.2%、乌司奴单抗28.9%、依那西普20.3%、司库奇尤单抗15%、英夫利西单抗3%、戈利木单抗1%、培塞利珠单抗0.6%。
- 基线(第0周)PASI评分范围为4至54,均值±标准差16.5±7.1。
- PASI评分在生物制剂给药后第16周为3.7±8、第28周为1.6±2.1、第52周为1.2±2.1。
- 266例老年银屑病患者中观察期间报告25例不良事件。
- 最常见不良事件为感染12例(48%),其次为恶性肿瘤4例(16%)。
临床怎么用
- 作者认为年龄本身不应限制银屑病生物制剂治疗选择。
- 作者认为需要进一步观察性研究使用多数据来源评估老年银屑病患者的长期疗效和安全性。
局限性
- 需要进一步观察性研究使用多数据来源评估老年银屑病患者的长期疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The number of elderly patients with psoriasis is steadily increasing in the Western world; nevertheless, they are frequently excluded from biological clinical trials and described as a high-risk group for adverse events. Thus, there is lack of information concerning safety and effectiveness of available treatments for psoriasis in the elderly, particularly about new biological systemic drugs. OBJECTIVE: Our aim was to describe our experience with all biological therapies currently used in the elderly (>65 years) psoriatic patients. METHODS: A retrospective multicentric review of clinical records of all psoriatic patient aged 65 years or older actually receiving biological drugs (etanercept, adalimumab, infliximab, golimumab, certolizumab pegol, ustekinumab or secukinumab) was undertaken. RESULTS: Our study population included 266 elderly psoriatic patients actually receiving any biological therapy (adalimumab 31.2%, ustekinumab 28.9%, etanercept 20.3%, secukinumab 15%, infliximab 3%, golimumab 1% and certolizumab pegol 0.6%). The PASI score at the baseline (week 0) ranged from 4 to 54; mean ± SD, 16.5 ± 7.1, which changed after biological administration to 3.7 ± 8 at week 16, 1.6 ± 2.1 at week 28 and 1.2 ± 2.1 at week 52. Among 266 elderly psoriatic patients, 25 adverse events were reported during the observation period. The most frequent events were infections with 12 (48%) reports, followed by malignancies with four (16%) reports. CONCLUSIONS: To date, our study represents the widest experience on the use of biological drugs in elderly psoriatic patients. We found that all biologics for psoriasis showed a great efficacy also in elderly people, and the rate and the type of adverse effects were similar to the younger patients. In conclusion, the age alone should not limit our therapeutic options. Further observational study using multiple data sources is needed to evaluate long-term effectiveness and safety for elderly psoriatic patients.
引用
- Ricceri F, Bardazzi F, Chiricozzi A, et al. Elderly psoriatic patients under biological therapies: an Italian experience. J Eur Acad Dermatol Venereol. 2018. PMID: 29906311. doi:10.1111/jdv.15139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。